Chemoradiation plus toripalimab for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a type of nasopharyngeal cancer called non-keratinizing carcinoma (WHO type II or III).
- Your cancer must be stage IVa (it has spread to lymph nodes but not to distant organs).
- You must not have received any previous treatment for this cancer (like chemotherapy or radiation).
- Your overall health should be good (ECOG score 0-1), meaning you can take care of yourself and do daily activities without help.
- You must not have other serious illnesses, autoimmune diseases, or infections like HIV or active hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial studies whether adding toripalimab to radiation plus chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. It also looks at tumor markers (like PD-L1) using stored tumor tissue or a new biopsy.
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.